Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 6, 2007 - Issue 1
Submit an article Journal homepage
439
Views
36
CrossRef citations to date
0
Altmetric
Editorial

Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?

Khalid A Osman Queen’s Hospital, Department of Surgery, Burton on Trent, Staffordshire, UK
,
Meissa M Osman Glenfield General Hospital, Department of Paediatric Cardiology, Leicester, UK
&
Mohamed H Ahmed Southampton General Hospital, Chemical Pathology Department, Mail point 6, Level D South Academic Block, Tremona Road, Southampton, SO16 6YD, UK. [email protected]
Pages 1-4 | Published online: 20 Dec 2006

Bibliography

  • PRATT DS, KNOX TA, ERBAN J: Tamoxifen-induced steatohepatitis. Ann. Intern. Med. (1995) 123(3):236.
  • AHMED MH, BYRNE CD: Non-alcoholic steatoheptatitis. In: Metabolic Syndrome. Byrne CD, Wild S (Eds), Wiley, UK (2005):279-303.
  • GRIECO A, FORGIONE A, MIELE L et al.: Fatty liver and drugs. Eur. Rev. Med. Pharmacol. Sci. (2005) 9(5):261-263.
  • BRUNO S, MAISONNEUVE P, CASTELLANA P et al.: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ (2005) 330(7497):932.
  • AHMED MH, OSMAN KA: Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. Breast Cancer Res. Treat. (2006) 97(2):223-224.
  • OHNISHI T, OGAWA Y, SAIBARA T et al.: CYP17 polymorphism and tamoxifen-induced hepatic steatosis. Hepatol. Res. (2005) 33(2):178-180.
  • PESSAYRE D, FROMENTY B, MANSOURI: Mitochondrial injury in steatohepatitis. Eur. J. Gastroenterol. Hepatol. (2004) 16:1095-1105.
  • COSKUN U, GUNEL N, TORUNER FB et al.: Serum leptin levels are associated with tamoxifen induced hepatic steatosis. Curr. Med. Res. Opin. (2003) 19(1):47-50.
  • AHMED MH, OSMAN KA, OSMAN MM: Invasive and non-invasive investigations for tamoxifen induced-non-alcoholic steatohepatitis (NASH): the benefit of computed tomography scan guided liver biopsy. Pathology (2006) 38(3):270-271.
  • IOANNOU GN, WEISS NS, BOYKO EJ, MOZAFFARIAN D, LEE SP: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology (2006) 43:1145-1151.
  • AHMED MH, SAAD RA, OSMAN MM: Ezetimibe: is effective and safe treatment for dyslipidaemia associated with non alcoholic fatty liver disease. Expert Opin. Drug Saf. (2006) 5(4):487-488.
  • AHMED MH: Rosuvastatin safe and effective treatment for dyslipidaemia associated with non alcoholic steatohepatitis (NASH). Scand. J. Gastroenterol. (2006) 41(5):613.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.